

Hyperphosphatemia Drugs Market Report by Product (Sevelamer, Calcium Based Phosphate Binders, Iron Based Phosphate Binders, Lanthanum Carbonate, and Others), Dosage Form (Tablets, Syrups, Capsules), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032

<https://marketpublishers.com/r/H3BC00DF90F6EN.html>

Date: April 2024

Pages: 137

Price: US\$ 3,899.00 (Single User License)

ID: H3BC00DF90F6EN

Abstracts

The global hyperphosphatemia drugs market size reached US\$ 4.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 7.07% during 2024-2032. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.

Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.

Hyperphosphatemia Drugs Market Trends:

The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global hyperphosphatemia drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, dosage form, and distribution channel.

Product Insights:

Sevelamer

Calcium Based Phosphate Binders

Iron Based Phosphate Binders

Lanthanum Carbonate

Others

The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the product. This includes sevelamer, calcium based phosphate

binders, iron based phosphate binders, lanthanum carbonate, and others. According to the report, sevelamer represented the largest segment.

Dosage Form Insights:

Tablets

Syrups

Capsules

The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the dosage form. This includes tablets, syrups, and capsules. According to the report, tablets represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the hyperphosphatemia drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?

What are the key regional markets?

Which countries represent the most attractive hyperphosphatemia drugs markets?

What is the breakup of the market based on the product?

What is the breakup of the market based on the dosage form?

What is the breakup of the market based on the distribution channel?

What is the competitive structure of the global hyperphosphatemia drugs market?

Who are the key players/companies in the global hyperphosphatemia drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY PRODUCT

- 6.1 Sevelamer
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 Calcium Based Phosphate Binders
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 Iron Based Phosphate Binders

- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Lanthanum Carbonate
 - 6.4.1 Market Trends
 - 6.4.2 Market Forecast
- 6.5 Others
 - 6.5.1 Market Trends
 - 6.5.2 Market Forecast

7 MARKET BREAKUP BY DOSAGE FORM

- 7.1 Tablets
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Syrups
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 7.3 Capsules
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast

8 MARKET BREAKUP BY DISTRIBUTION CHANNEL

- 8.1 Hospital Pharmacies
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
- 8.3 Online Pharmacies
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast

9 MARKET BREAKUP BY REGION

- 9.1 North America
 - 9.1.1 United States
 - 9.1.1.1 Market Trends
 - 9.1.1.2 Market Forecast

9.1.2 Canada

9.1.2.1 Market Trends

9.1.2.2 Market Forecast

9.2 Asia-Pacific

9.2.1 China

9.2.1.1 Market Trends

9.2.1.2 Market Forecast

9.2.2 Japan

9.2.2.1 Market Trends

9.2.2.2 Market Forecast

9.2.3 India

9.2.3.1 Market Trends

9.2.3.2 Market Forecast

9.2.4 South Korea

9.2.4.1 Market Trends

9.2.4.2 Market Forecast

9.2.5 Australia

9.2.5.1 Market Trends

9.2.5.2 Market Forecast

9.2.6 Indonesia

9.2.6.1 Market Trends

9.2.6.2 Market Forecast

9.2.7 Others

9.2.7.1 Market Trends

9.2.7.2 Market Forecast

9.3 Europe

9.3.1 Germany

9.3.1.1 Market Trends

9.3.1.2 Market Forecast

9.3.2 France

9.3.2.1 Market Trends

9.3.2.2 Market Forecast

9.3.3 United Kingdom

9.3.3.1 Market Trends

9.3.3.2 Market Forecast

9.3.4 Italy

9.3.4.1 Market Trends

9.3.4.2 Market Forecast

9.3.5 Spain

- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES

- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Ardelyx Inc.

14.3.1.1 Company Overview

14.3.1.2 Product Portfolio

14.3.1.3 Financials

14.3.2 Fresenius Medical Care AG & Co. KGaA

14.3.2.1 Company Overview

14.3.2.2 Product Portfolio

14.3.2.3 Financials

14.3.2.4 SWOT Analysis

14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)

14.3.3.1 Company Overview

14.3.3.2 Product Portfolio

14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)

14.3.4.1 Company Overview

14.3.4.2 Product Portfolio

14.3.4.3 Financials

14.3.5 Vifor Pharma Management Ltd. (CSL Limited)

14.3.5.1 Company Overview

14.3.5.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List Of Tables

LIST OF TABLES

Table 1: Global: Hyperphosphatemia Drugs Market: Key Industry Highlights, 2023 & 2032

Table 2: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Product (in Million US\$), 2024-2032

Table 3: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Dosage Form (in Million US\$), 2024-2032

Table 4: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Distribution Channel (in Million US\$), 2024-2032

Table 5: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 6: Global: Hyperphosphatemia Drugs Market: Competitive Structure

Table 7: Global: Hyperphosphatemia Drugs Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Hyperphosphatemia Drugs Market: Major Drivers and Challenges

Figure 2: Global: Hyperphosphatemia Drugs Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Billion US\$), 2024-2032

Figure 4: Global: Hyperphosphatemia Drugs Market: Breakup by Product (in %), 2023

Figure 5: Global: Hyperphosphatemia Drugs Market: Breakup by Dosage Form (in %), 2023

Figure 6: Global: Hyperphosphatemia Drugs Market: Breakup by Distribution Channel (in %), 2023

Figure 7: Global: Hyperphosphatemia Drugs Market: Breakup by Region (in %), 2023

Figure 8: Global: Hyperphosphatemia Drugs (Sevelamer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 9: Global: Hyperphosphatemia Drugs (Sevelamer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 10: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 11: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 12: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 13: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 14: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 15: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 16: Global: Hyperphosphatemia Drugs (Other Products) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 17: Global: Hyperphosphatemia Drugs (Other Products) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 18: Global: Hyperphosphatemia Drugs (Tablets) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 19: Global: Hyperphosphatemia Drugs (Tablets) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 20: Global: Hyperphosphatemia Drugs (Syrups) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 21: Global: Hyperphosphatemia Drugs (Syrups) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 22: Global: Hyperphosphatemia Drugs (Capsules) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 23: Global: Hyperphosphatemia Drugs (Capsules) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 24: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 25: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 26: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 27: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 28: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 29: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 30: North America: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 31: North America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 32: United States: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 33: United States: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 34: Canada: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 35: Canada: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 36: Asia-Pacific: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 37: Asia-Pacific: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 38: China: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 39: China: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million

US\$), 2024-2032

Figure 40: Japan: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 41: Japan: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 42: India: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 43: India: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 44: South Korea: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 45: South Korea: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 46: Australia: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 47: Australia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 48: Indonesia: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 49: Indonesia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 50: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 51: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 52: Europe: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 53: Europe: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 54: Germany: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 55: Germany: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 56: France: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 57: France: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 58: United Kingdom: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 59: United Kingdom: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 60: Italy: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 61: Italy: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 62: Spain: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 63: Spain: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 64: Russia: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 65: Russia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 66: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 67: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 68: Latin America: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 69: Latin America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 70: Brazil: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 71: Brazil: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 72: Mexico: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 73: Mexico: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 74: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 75: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 76: Middle East and Africa: Hyperphosphatemia Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 77: Middle East and Africa: Hyperphosphatemia Drugs Market: Breakup by Country (in %), 2023

Figure 78: Middle East and Africa: Hyperphosphatemia Drugs Market Forecast: Sales

Value (in Million US\$), 2024-2032

Figure 79: Global: Hyperphosphatemia Drugs Industry: Drivers, Restraints, and Opportunities

Figure 80: Global: Hyperphosphatemia Drugs Industry: Value Chain Analysis

Figure 81: Global: Hyperphosphatemia Drugs Industry: Porter's Five Forces Analysis

I would like to order

Product name: Hyperphosphatemia Drugs Market Report by Product (Sevelamer, Calcium Based Phosphate Binders, Iron Based Phosphate Binders, Lanthanum Carbonate, and Others), Dosage Form (Tablets, Syrups, Capsules), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032

Product link: <https://marketpublishers.com/r/H3BC00DF90F6EN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H3BC00DF90F6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970